Gilead Sciences has agreed a deal with machine-learning start-up Insitro to help the drug maker develop treatments for liver disease. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners. Insitro will pay an initial $15 million to the SAN FRANCISCO -based start-up, with a potential $ first in payments at later dates if certain targets are met. Through the deal, Insitro will develop and apply machine algorithms to the task of identifying proteins that could be targets for innovative drugs to treat non-alcoholic steatohepatitis, or Insitro .
Gilead Sciences has agreed a deal with machine-learning start-up Insitro to help the drug maker develop treatments for liver disease. Insitro will pay an initial $15 million to the SAN FRANCISCO -based start-up, with a potential $ first in payments at later dates if certain targets are met. Through the deal, Insitro will develop and apply machine algorithms to the task of identifying proteins that could be targets for innovative drugs to treat non-alcoholic steatohepatitis, or Insitro .